BioMarin Pharmaceutical Inc. (BMRN) Financials Nov
Post# of 250602
Posted On: 11/20/2014 7:56:12 PM
BioMarin Pharmaceutical Inc. (BMRN) Financials Nov 20, 2014, 5:32 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for BioMarin Pharmaceutical Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 324.66M 376.27M 446M 494.89M 548.45M
Cost of Goods Sold (COGS) incl. D&A 68.82M 76.69M 119.15M 129.95M 136.21M
COGS excluding D&A 47.85M 46.99M 83.06M 84.65M 88.94M
Depreciation & Amortization Expense 20.98M 29.71M 36.09M 45.3M 47.26M
Depreciation 18.06M 23.3M 31.9M 34.9M 36.5M
Amortization of Intangibles 2.91M 6.41M 4.19M 10.4M 10.76M
Gross Income 255.83M 299.58M 326.84M 364.94M 412.24M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 239.41M 299.03M 358.57M 464.82M 550.83M
Research & Development 115.12M 147.31M 214.37M 302.22M 354.78M
Other SG&A 124.29M 151.72M 144.2M 162.6M 196.05M
Other Operating Expense 0 0 0 0 0
Unusual Expense 5.85M 13.73M 4.06M 10.34M 30.42M
EBIT after Unusual Expense (5.85M) (13.73M) (4.06M) (10.34M) (30.42M)
Non Operating Income/Expense 1.59M 902,000 0 (1.79M) 1.02M
Non-Operating Interest Income 5.09M 4.11M 2.93M 2.58M 3.08M
Equity in Affiliates (Pretax) (2.59M) (2.99M) (2.43M) (1.22M) (1.15M)
Interest Expense 14.09M 10.33M 8.35M 7.64M 10.45M
Gross Interest Expense 14.09M 10.33M 8.35M 14.94M 10.45M
Interest Capitalized 0 0 0 7.3M 0
Pretax Income 566,000 (21.49M) (43.63M) (118.28M) (176.5M)
Income Tax 1.05M (227.31M) 10.21M (3.93M) (150,000)
Income Tax - Current Domestic (379,000) 1.64M 4.21M 4.13M 6.56M
Income Tax - Current Foreign 1.43M 1.62M 1.64M 1.86M 2.2M
Income Tax - Deferred Domestic 0 (230.17M) 4.44M (9.95M) (8.74M)
Income Tax - Deferred Foreign 0 (404,000) (78,000) 25,000 (163,000)
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 - - 0 0
Consolidated Net Income (488,000) 205.82M (53.84M) (114.35M) (176.35M)
Minority Interest Expense 0 0 0 0 0
Net Income (488,000) 205.82M (53.84M) (114.35M) (176.35M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - - - 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (488,000) 205.82M (53.84M) (114.35M) (176.35M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (488,000) 205.82M (53.84M) (114.35M) (176.35M)
EPS (Basic) 0.00 2.00 (0.48) (0.95) (1.28)
Basic Shares Outstanding 100.27M 103.09M 112.12M 120.27M 137.76M
EPS (Diluted) 0.00 1.64 (0.48) (0.95) (1.28)
Diluted Shares Outstanding 100.27M 125.67M 112.12M 120.27M 137.76M
EBITDA 37.4M 30.25M 4.37M (54.58M) (91.33M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for BioMarin Pharmaceutical Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 324.66M 376.27M 446M 494.89M 548.45M
Cost of Goods Sold (COGS) incl. D&A 68.82M 76.69M 119.15M 129.95M 136.21M
COGS excluding D&A 47.85M 46.99M 83.06M 84.65M 88.94M
Depreciation & Amortization Expense 20.98M 29.71M 36.09M 45.3M 47.26M
Depreciation 18.06M 23.3M 31.9M 34.9M 36.5M
Amortization of Intangibles 2.91M 6.41M 4.19M 10.4M 10.76M
Gross Income 255.83M 299.58M 326.84M 364.94M 412.24M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 239.41M 299.03M 358.57M 464.82M 550.83M
Research & Development 115.12M 147.31M 214.37M 302.22M 354.78M
Other SG&A 124.29M 151.72M 144.2M 162.6M 196.05M
Other Operating Expense 0 0 0 0 0
Unusual Expense 5.85M 13.73M 4.06M 10.34M 30.42M
EBIT after Unusual Expense (5.85M) (13.73M) (4.06M) (10.34M) (30.42M)
Non Operating Income/Expense 1.59M 902,000 0 (1.79M) 1.02M
Non-Operating Interest Income 5.09M 4.11M 2.93M 2.58M 3.08M
Equity in Affiliates (Pretax) (2.59M) (2.99M) (2.43M) (1.22M) (1.15M)
Interest Expense 14.09M 10.33M 8.35M 7.64M 10.45M
Gross Interest Expense 14.09M 10.33M 8.35M 14.94M 10.45M
Interest Capitalized 0 0 0 7.3M 0
Pretax Income 566,000 (21.49M) (43.63M) (118.28M) (176.5M)
Income Tax 1.05M (227.31M) 10.21M (3.93M) (150,000)
Income Tax - Current Domestic (379,000) 1.64M 4.21M 4.13M 6.56M
Income Tax - Current Foreign 1.43M 1.62M 1.64M 1.86M 2.2M
Income Tax - Deferred Domestic 0 (230.17M) 4.44M (9.95M) (8.74M)
Income Tax - Deferred Foreign 0 (404,000) (78,000) 25,000 (163,000)
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 - - 0 0
Consolidated Net Income (488,000) 205.82M (53.84M) (114.35M) (176.35M)
Minority Interest Expense 0 0 0 0 0
Net Income (488,000) 205.82M (53.84M) (114.35M) (176.35M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - - - 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (488,000) 205.82M (53.84M) (114.35M) (176.35M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (488,000) 205.82M (53.84M) (114.35M) (176.35M)
EPS (Basic) 0.00 2.00 (0.48) (0.95) (1.28)
Basic Shares Outstanding 100.27M 103.09M 112.12M 120.27M 137.76M
EPS (Diluted) 0.00 1.64 (0.48) (0.95) (1.28)
Diluted Shares Outstanding 100.27M 125.67M 112.12M 120.27M 137.76M
EBITDA 37.4M 30.25M 4.37M (54.58M) (91.33M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
(0)
(0)Scroll down for more posts ▼